Neurescue has received CE Mark approval for its NEURESCUE® device, becoming the first medical technology cleared in Europe to treat non-shockable cardiac arrest.
The approval, granted by TÜV SÜD under the EU Medical Device Regulation after a six-month review, represents one of the most important developments in resuscitation since the introduction of CPR in 1960.
Around four in five cardiac arrest cases present as non-shockable and therefore cannot be treated with defibrillation. Survival rates for these patients currently stand at about four per cent.
The NEURESCUE device aims to improve outcomes by directly targeting this high-risk group. With European approval now secured, the technology is expected to be made available internationally.
The system combines a catheter with a handheld control unit. By inflating a soft balloon inside the descending aorta, it redirects blood flow towards the heart and brain during cardiopulmonary resuscitation.
This improves circulation to vital organs within a minute of use and may help restore a heartbeat while providing time for other advanced interventions, including extracorporeal support or coronary procedures. Automated inflation and built-in sensors guide the process for accuracy and safety.
Clinical testing has shown high success rates with a short average procedure time. Simulated trials indicate that the device can be used by both hospital clinicians and emergency responders, including paramedics and military medics, supporting its wider potential use.
In addition to European authorisation, the NEURESCUE device also holds US FDA 510(k) clearance for emergency haemorrhage control.
